Literature DB >> 29590540

Osimertinib in EGFR Mutation-Positive Advanced NSCLC.

Jean-Charles Soria1, Suresh S Ramalingam2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29590540     DOI： 10.1056/NEJMc1801669

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

1.  Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.

Authors:  Shuyan Meng; Guorui Wang; Yang Lu; Zhen Fan
Journal:  Lung Cancer       Date:  2018-05-01       Impact factor: 5.705

2.  Prevalence and Significance of Potential Pharmacokinetic Drug-Drug Interactions Among Patients with Lung Cancer: Implications for Clinical Trials.

Authors:  Sawsan Rashdan; Hui Yang; Tri Le; Christopher Selby; David E Gerber; Carlos A Alvarez
Journal:  Clin Drug Investig       Date:  2021-01-08       Impact factor: 2.859

3.  An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.

Authors:  Ciric To; Tyler S Beyett; Jaebong Jang; William W Feng; Magda Bahcall; Heidi M Haikala; Bo H Shin; David E Heppner; Jaimin K Rana; Brittaney A Leeper; Kara M Soroko; Michael J Poitras; Prafulla C Gokhale; Yoshihisa Kobayashi; Kamal Wahid; Kari J Kurppa; Thomas W Gero; Michael D Cameron; Atsuko Ogino; Mierzhati Mushajiang; Chunxiao Xu; Yanxi Zhang; David A Scott; Michael J Eck; Nathanael S Gray; Pasi A Jänne
Journal:  Nat Cancer       Date:  2022-04-14

Review 4.  Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy.

Authors:  Adriana Petrazzuolo; M Chiara Maiuri; Laurence Zitvogel; Guido Kroemer; Oliver Kepp
Journal:  Oncoimmunology       Date:  2022-05-26       Impact factor: 7.723

5.  Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.

Authors:  Da Hyun Kang; Sung Soo Jung; Min-Kyung Yeo; Da Hye Lee; Geon Yoo; Sang Yeon Cho; In-Jae Oh; Ju-Ock Kim; Hee Sun Park; Chaeuk Chung; Jeong Eun Lee
Journal:  BMC Cancer       Date:  2020-06-18       Impact factor: 4.430

Review 6.  Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer.

Authors:  Roxana Reyes; Noemi Reguart
Journal:  Transl Lung Cancer Res       Date:  2021-01

Review 7.  FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management.

Authors:  Isabelle Solassol; Frédéric Pinguet; Xavier Quantin
Journal:  Biomolecules       Date:  2019-10-30

8.  Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China.

Authors:  Qiao Liu; Xia Luo; Liubao Peng; Lidan Yi; Xiaomin Wan; Xiaohui Zeng; Chongqing Tan
Journal:  BMJ Open       Date:  2020-11-26       Impact factor: 2.692
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.